KPMG

Repositioning Nigeria's Pharmaceutical Industry: From Constraints to Competitiveness

July 2026

home.kpmg/ng

Outline

Kindly click on each topic to navigate directly to its corresponding page within the document.

Executive summary

Nigeria's pharmaceutical sector is structurally import-dependent, particularly for Active Pharmaceutical Ingredients (APIs) and Excipients, over 90% of which are sourced externally. Consequently, the sector has been historically exposed to foreign exchange volatility and global supply disruptions. This is in stark contrast to the country's status as one of Africa's largest economies as Nigeria serves as a consumption market, with limited export competitiveness compared to peers such as South Africa and Egypt.

Several structural headwinds constrain the sector, apart from its high import-dependence and strong exposure to exchange rate volatility. Logistics and infrastructure deficits -particularly port congestion, weak road networks, and severe cold-chain limitations- extend lead times and raise operating costs. Also, access to affordable capital is constrained by high interest rates, limiting the ability of firms to scale, modernize, and compete globally. In addition, the limited domestic production of APIs and excipients reinforces supply vulnerability, while low adoption of digital technologies restricts supply chain visibility and efficiency. The continued prevalence of counterfeit medicines poses both a public health and commercial risk, and talent shortages, especially in digitally enabled and regulatory-compliant supply chain roles, further constrain industry development.

But the sector is now undergoing a transformational shift, supported by policy reforms, increasing local manufacturing capacity, and strong underlying demand fundamentals.

The outlook for Nigeria's pharmaceutical industry remains strongly positive. Demand is underpinned by powerful structural drivers, including a population of approximately 240 million people, a high burden of infectious diseases, a rising incidence of non-communicable diseases, rapid urbanisation, and sustained out-of-pocket healthcare spending.

On the supply side, regulatory reforms are increasingly reshaping incentives that are redefining the landscape. Policies such as the "5+5" localisation directive, the expansion of contract manufacturing, the introduction of Medipool as a national group purchasing organisation, and the rollout of mandatory product traceability systems are collectively improving market structure, quality assurance, and investment attractiveness.

Global case studies, particularly from India and Bangladesh, demonstrate that sustained success in pharmaceutical industrialisation is driven by deliberate and coordinated policy action, including, targeted protection of domestic markets, and incentives tied directly to production and export performance, and the strategic use of intellectual property frameworks. These experiences reinforce the importance of long-term commitment and policy consistency in building globally competitive pharmaceutical ecosystems.

To fully unlock its potential, Nigeria must accelerate its transition from an import-dependent system to a resilient and competitive manufacturing hub. Central to this transformation is the localisation of API production as a matter of national health and economic security, alongside stronger alignment between production and aggregated demand platforms such as Medipool.

At the same time, investments in modern cold-chain infrastructure, particularly solar-powered systems, will enhance distribution reliability, while a sequenced rollout of digital supply chain technologies can significantly improve efficiency, forecasting, and decision-making. These priorities will help to define a clear pathway not only for strengthening domestic capacity but for positioning Nigeria as a credible pharmaceutical manufacturing and export leader in the region.

Industry overview

Conservative estimates value Nigeria's pharmaceutical market at around US$2 billion; however, more comprehensive assessments that capture the broader supply chain suggest that this valuation may be substantially higher[1].



Source: Nigeria Private Health Sector Market Outlook (2026), KPMG Research

The number of pharmaceutical firms operating in Nigeria rose from 115 to 186 between 2018 and 2024, while pharmaceutical production more than doubled correspondingly within the same period[2]. Despite this progress, local production capacity remains insufficient to fully substitute for imports- the legacy environment was such that 70% of local pharmaceutical needs were met by imports before the gains now being recorded on the back of policy and industrial momentum in the sector.

Furthermore, despite being one of the four largest economies in Africa, Nigeria's pharmaceutical industry continues to punch below its weight in export competitiveness, lagging significantly behind peers such as South Africa and Egypt. The country primarily serves as a consumption market, with domestic demand being met largely through imports. These dynamics historically reduced the incentive for local firms to scale production for export, as they face intense competition from established global manufacturers within their own domestic market.



Source: ITC - UN Comtrade, World Bank Group (Country Private Sector Diagnostic Report for Nigeria), KPMG Research

[1] The Pharmaceutical Export Promotion Council of India (Pharmexcil) values the market as high as US$4.5 billion (2023)

[2] see World Bank Group's Country Private Sector Diagnostic Report for Nigeria

Pharmaceutical value chain

Understanding where value is captured, and more critically where value is destroyed, is essential to identifying the highest-leverage points for both market entry and industrial policy intervention. Nigeria's pharmaceutical value chain runs from the import of raw chemical inputs through domestic formulation and packaging to a highly fragmented retail and distribution system. It is also marked by thin domestic value addition at the upstream and midstream levels, and some inefficiencies at the downstream level. The result is a market that is simultaneously expensive for consumers and with margin pressures for local manufacturers

	UPSTREAM				MIDSTREAM		DOWNSTREAM		
	Research & Developement (R & D)	Active pharmarceutical ingredients (API) production	Excipients & Packaging Inputs	Local Manufacturing Formulation	Importation (Finished Products)	Quality Control & Regulation	Distribution (Wholesale)	Retail (Last - Mile Access)	Consumption (Patients & Health System)
What happens	Drug discovery, preclinical studies, clinical trials, formulation development.	Manufacture of active ingredients (the core therapeutic substances).	Production/ import of excipients (fillers, binders, etc.) and packaging materials.	Formulation of drugs (tablets, capsules, syrups, injectables), packaging and labeling.	Importation of finished pharmaceu-tical products.	Product registration, GMP inspection, quality testing, pharmacovi-gilance and market surveillance.	Movement from manufacturers/ importers to wholesalers, distributors and drug markets.	Sale through pharmacies, PMVs, hospitals and clinics to end users.	Patients use medicines for prevention, treatment and wellness.
Key players	- Nigerian Institute of Medical Research(NIMR) - Universities - Teaching hospitals - NAFDAC (Trials oversight)	- Mostly foreign manufactu-rers (India, China) - Few/No local API producers	- Global suppliers - Local packaging companies (emerging)	- Fidson Healthcare - Emzor - May & Baker - Neimeth - Orito	- Importers - Trading Companies - Multinational Pharma Companies	- NAFDAC - Pharmacists Council of Nigeria - Standards Organisation of Nigeria (SON)	- Licensed Distributors - Super Stockists - Open Drug Markets (Idumota, Onitsha)	- Pharmacies - Patent Medicine Vendors (PMVs) - Hospitals & Clinics - E-commerce (growing)	- Patients - Households - Health Facilities - Insurance (growing)
Nigeria reality	- Very limited originator R&D - Generic formulation focus - Under-funded research ecosystem	- ~90–100% - import dependence - No meaningful local API base	- Mostly imported - Local packaging capacity development	- Capacity utilization: ~40–50% - FX constraints - High energy costs - Good Manufacturing Practice (GMP) gaps	- ~60–75% of medicines imported - Strong competition from Asia	- Strengthening regulatory system - WHO Maturity Level 3 achieved - Pharmacovi-gilance improving	- Fragmented structure - Informal markets dominant - Counterfeit penetration risk	- PMVs are largest access channel - Rural access weak - Out-of-pocket payments high	- High disease burden (NCDs, infectious diseases) - ~70%+ out-of-pocket spending
Key challenges:	Low funding, weak innovation incentives.	Weak local API industry, FX exposure.	Industrial base shallow, import reliance.	High cost of production, power, FX, compliance.	Forex shortage, import dependence.	Compliance gaps, limited labs, enforcement capacity.	Poor infrastructure, logistics, weak data systems.	Informality, quality assurance at last-mile.	Affordability, low insurance coverage.

Key facts:

- **~240M+** population driving pharmaceu-tical demand
- **70%** of medicines imported in thelegacy environment
- **186** registered local pharmaceutical manufacturers
- **~90–100%** dependence on imported APIs
- **70%+** medicines sold through informal sector (PMVs & open markets)
- **~70%+** out-of-pocket health expenditure
- High burden of NCDs, infectious diseases and maternal & child health conditions

Source: Industry Reports, NAFDAC, PCN, NBS, WHO, Dalberg Analysis, KPMG Research

Where the chain is strongest (Improving)

- local formulation capacity
- regulatory quality systems
- industrial policy momentum.

Where the chain remains weakest (Structurally fragile)

- APIs
- pharmaceutical raw materials
- formal wholesale distribution
- cold-chain logistics
- traceability

Critical supply chain constraints

The Nigerian pharmaceutical supply chain operates within a complex web of structural constraints that have historically challenged operational efficiency.



Exchange rate exposure

Although the Naira has stabilised in recent times, high exchange rate remains a major structural challenge confronting Nigerian pharmaceutical operators. With over 90% of active pharmaceutical ingredients (APIs) and a significant proportion of finished dosage forms sourced externally, elevated exchange rate translates directly into significant raw materials cost escalation that may squeeze business margins and dampen competitiveness in regional and global markets.



Logistics infrastructure constraints

Nigeria's logistics landscape presents a paradox: despite being the fourth largest economy in Africa, Nigeria's infrastructure falls significantly short of the demands of a modern pharmaceutical supply chain. Port efficiency remains a critical bottleneck, for instance. Inefficient demurrage practices at Apapa and Tin Can ports where vessels can wait 10-21 days before berthing, add substantial landed costs and introduce unpredictable delays into import-dependent supply chains.

Combined with poor road infrastructure in key South-West corridors and inadequate cold chain connectivity in Northern regions, pharmaceutical lead times are significantly prolonged, far exceeding global benchmarks of 4-6 weeks for comparable routes. The cold chain deficit represents a particularly urgent vulnerability. Nigeria's cold storage capacity remains severely limited in terms of functional, temperature-controlled infrastructure- a shortfall that is starkly inadequate for a country of this size and for a pharmaceutical sector with an expanding biologics portfolio.



Capital constraints

High borrowing costs which limit access to capital is another headwind confronting Nigeria's pharmaceutical sector- Nigeria's monetary policy rate currently stands at 26.5%. Interest rates at such double-digit high may put a structural lid on the expansion of the real sector which the pharmaceutical sector is an important part of. Many manufacturers lack the funding to develop new products, upgrade outdated facilities, and meet global quality standards. Without structured financing and technical support, smaller and mid-sized firms cannot scale or compete effectively, while even larger players struggle to invest confidently. Strengthening access to capital, alongside enforcing higher production standards, is essential for growth and competitiveness in the industry.



Source: CBN, KPMG Research

Quality excipients and active ingredients

Most active ingredients and excipients are imported from India, China, the United States, and Europe. As a result, the country faced significant API shortage and skyrocketing pharmaceutical costs amid the global supply chain dislocation that followed the outbreak of the COVID- 19 pandemic. Also, despite Nigeria's capacity to grow reasonable quantities of cassava and maize, domestic production of excipients like pharmaceutical-grade starch and essential oils remains largely stalled, although some progress has been made on exploring local API production.

Two local pharmaceutical manufacturers have carried out initial assessments of the feasibility of manufacturing APIs in Nigeria. One has already built an antimalarial API plant in Lagos, with a technology transfer and licensing agreement from their Indian manufacturing partner. Additionally, following the completion of their excipients' feasibility study, Nigeria Sovereign Investment Authority (NSIA) signed a technology-transfer agreement with a leading Indian chemical-grade starch producer, to start Nigerian production soon.

Technology & digital transformation gaps

Investment in digital and advanced technologies remains one of the most significant opportunities to strengthen Nigeria's pharmaceutical supply chain. Although industry stakeholders increasingly recognise the strategic importance of digital transformation, multiple studies show that the practical adoption of advanced tools such as AI driven planning systems and integrated supply chain visibility solutions, remains limited across the sector.

The COVID- 19 pandemic created a forced acceleration, driving changes in months that might otherwise have taken a decade, but the momentum has been uneven. Larger firms tend to show higher awareness and adoption of emerging digital and Industry 4.0 technologies, while many mid sized and indigenous manufacturers continue to face challenges such as limited finance, insufficient technical expertise, and gaps in infrastructure, which hinder effective digital transformation.

Drug counterfeiting & supply chain integrity

The prevalence of substandard and falsified medicines represents both a critical public health crisis and a fundamental commercial threat to legitimate pharmaceutical operators. Blockchain-based track-and-trace solutions are being explored, including technology pilots aimed at improving transparency and authentication. However, the transition from paper-based documentation to digital verification requires coordinated investment across manufacturers, distributors, retailers, and the NAFDAC enforcement apparatus simultaneously.

Effective anti-counterfeiting strategy requires three simultaneous capabilities: prevention (serialisation and authentication at the point of manufacture), detection (real-time verification at distribution nodes and retail points), and response (rapid supply chain quarantine and regulatory action upon detection). Nigeria's current capabilities are strongest in prevention frameworks (through GS1 serialization mandates) and weakest in real-time detection and coordinated response.

The talent crisis

There is a shortage of supply chain professionals with the technical proficiency, regulatory knowledge, and digital fluency required by modern pharmaceutical operations, and Nigeria faces an acute version of this challenge. The competition for talent is intensifying as multinationals, government agencies, and well-funded startups all pursue a limited pool of experienced supply chain leaders. Retention is equally problematic: Nigeria's pharmaceutical sector struggles to match the compensation packages and career development opportunities available in sectors such as financial services, oil and gas, and international organisations operating in the country.

The workforce of the future for Nigerian pharmaceutical supply chains will need to integrate capabilities across data analytics and AI interpretation, regulatory affairs expertise, Environmental, Social and Governance (ESG) measurement and reporting, cross-border logistics management, and strategic scenario planning. Building this competency base requires long-term investment in university partnerships, professional certification programs, and internal development frameworks, investments that few Nigerian pharmaceutical companies have made systematically.

Industry outlook

The outlook for Nigeria's pharmaceutical industry remains broadly positive, underpinned by resilient demand fundamentals, a gradually strengthening supply ecosystem, and regulatory transformations as reforms deepen and implementation momentum picks up within the sector.

Demand fundamentals remain structurally resilient

On the demand front, Nigeria's pharmaceutical demand remains structurally supported by a confluence of demographic, epidemiological, and healthcare financing dynamics:

Largest pharmaceutical market by population:

Nigeria's population is estimated at about 240 million people, cementing its place as Africa's most populous country and largest pharmaceutical market in West Africa.

High infectious disease burden:

Nigeria accounts for about 27% of the global malaria burden, while the prevalence of tuberculosis, HIV, and recurrent outbreaks continues to sustain baseline demand for essential medicines.

Rising non-communicable diseases (NCDs):

Cardiovascular disease, diabetes, cancers, and chronic respiratory conditions now driving steady demand for long term and chronic therapies.

Rapid urbanisation and demographic transition

Accelerating urban migration, changing lifestyles, and increased health seeking behaviour are expanding demand beyond acute care toward chronic and preventive treatments.

High private healthcare spending:

Out of pocket (OOP) expenditure remains the dominant funding mechanism for healthcare, sustaining private pharmaceutical consumption. Although Nigeria's OOP spending recently declined to about 58%, it still ranks among the highest globally with households remaining the single largest driver of pharmaceutical demand that provides volume resilience even during downturns.

Supply side evolution and regulatory momentum

On the supply side, the industry is benefiting from regulatory modernisation and industrial policy alignment. NAFDAC has consolidated its WHO Maturity Level 3 (ML3) status, signalling a stable and internationally credible regulatory environment, while targeting ML4 over the medium term through digitalisation and AI driven oversight.

Key reforms reshaping the sector include:

- The "5+5" localisation directive, linking product registration renewals to demonstrable local manufacturing or technology transfer plans.
- Facility layout approvals and contract manufacturing expansion, with approved pharmaceutical plants rising sharply and contract manufacturing firms expanding from about 30 in 2019 to over 87 by 2024, contributing to a marked reduction in finished drug imports.
- Mandatory product traceability and bioequivalence frameworks, strengthening quality assurance, reducing counterfeit penetration, and improving therapeutic confidence in locally manufactured generics.

Local pharmaceutical production is now estimated to meet roughly 50% of domestic demand, up from 30% prior to recent reforms, with incentives under the 2024–2025 Health Value Chain Executive Orders further improving cost competitiveness and investment attractiveness within the sector.

Favourable dynamics at play

Operational pillar	Legacy environment	What has changed
Sourcing strategy	Extreme import dependence (70%+).	Government mandate to reduce finished drug imports to 30% by 2025.
Registration pathway	Lengthy, repetitive local reviews take 1-2years.	NAFDAC Reliance Guidelines now allow for accelerated review leveraging trusted foreign approvals.
Manufacturing scale	Fragmented ecosystem with few manufacturers operating on a large scale.	**NAFDAC 5+5 Policy:** 70% of ceiling-listed medicines now targeted for local production.
Procurement model	Price volatility and disorganized purchasing.	**Medipool GPO:** National Group Purchasing Organization now aggregates demand and stabilize pricing.
Supply chain visibility	Manual, paper-based tracking with poor auditability.	**Traceability 2.0:** Mandated GS1 serialization and National Traceability Information System for vaccinations.



Case studies

We draw transformative lessons from select economies that have used coordinated policy, legal frameworks, and industrial incentives to build competitive pharmaceutical manufacturing ecosystems and scale domestic production to global markets.

Case Study 1: The Indian Model

Initial context	• India's pharmaceutical industry in the 1960s was dominated by multinational companies and characterised by minimal local manufacturing capability for complex APIs or formulations. • The country had scientific talent and a developing chemical industry, but no framework that enabled domestic firms to compete with established global players.
Strategies	• The Patents Act of 1970 redefined patentability for pharmaceuticals by granting patent protection only to manufacturing processes, not to chemical compounds themselves. This enabled Indian companies to reverse-engineer branded drugs through alternative synthesis routes and sell them as generics without infringing product patents. The Act effectively created a legal framework for generic competition that persisted until India's Trade-Related Aspects of Intellectual Property Rights (TRIPS) compliance in 2005. • The government imposed high import tariffs on finished pharmaceuticals and restricted foreign direct investment in the sector, creating protected market space for Indian companies to build scale and capabilities before facing full international competition. • India's government supported the development of pharmaceutical industrial clusters that provided shared infrastructure, regulatory proximity, and talent pools that reduced per-firm operating costs and accelerated knowledge sharing. • More recently, India's Production-Linked Incentive (PLI) scheme for pharmaceuticals (2020 onward) provides fiscal incentives linked to incremental production, specifically targeting high-value generic medicines, complex generics, and API manufacturing. The PLI has supported revival of domestic Penicillin G manufacturing (the foundation of the entire penicillin antibiotic class) which had been entirely outsourced to China.

Outcomes	• **Market scale:** India's pharmaceutical industry achieved massive scale valued at about USD 50 billion in FY 2023–24. • **Global market penetration:** India supplies approximately half of all generic prescriptions in the United States by volume, and exports to over 200 countries. It is the world's largest vaccine manufacturer by volume, accounting for over 60 percent of global production. • **Regulatory recognition:** India is home to the largest number of US FDA-compliant pharmaceutical plants outside the United States (over 262, including API facilities), approximately 1,400 WHO-GMP approved plants, and 253 European EDQM-approved plants. • **Export trajectory:** Indian pharmaceutical exports grew from approximately USD 6 billion in 2010 to USD 25.3 billion in 2024, and the sector has set an ambition to reach USD 450 billion by 2047.
Lessons for Nigeria	• The Patents Act of 1970 redefined patentability for pharmaceuticals by granting patent protection only to manufacturing processes, not to chemical compounds themselves. This enabled Indian companies to reverse-engineer branded drugs through alternative synthesis routes and sell them as generics without infringing product patents. The Act effectively created a legal framework for generic competition that persisted until India's Trade-Related Aspects of Intellectual Property Rights (TRIPS) compliance in 2005. • The government imposed high import tariffs on finished pharmaceuticals and restricted foreign direct investment in the sector, creating protected market space for Indian companies to build scale and capabilities before facing full international competition. • India's government supported the development of pharmaceutical industrial clusters that provided shared infrastructure, regulatory proximity, and talent pools that reduced per-firm operating costs and accelerated knowledge sharing. • More recently, India's Production-Linked Incentive (PLI) scheme for pharmaceuticals (2020 onward) provides fiscal incentives linked to incremental production, specifically targeting high-value generic medicines, complex generics, and API manufacturing. The PLI has supported revival of domestic Penicillin G manufacturing (the foundation of the entire penicillin antibiotic class) which had been entirely outsourced to China.

Case Study 2: The Bangladesh Model

Initial context	• In the early 1980s, Bangladesh's pharmaceutical sector was almost entirely dominated by multinational companies, with over 75 percent of the domestic market controlled by foreign firms. The country was essentially a pure import-dependent market. • Local manufacturers were small, technologically backward, and commercially marginal. Bangladesh had no meaningful API production capacity, limited human capital in pharmaceutical chemistry, and a regulatory environment that did not actively support domestic industry.
Strategies	• **Drug (control) ordinance 1982:** The landmark policy intervention was the 1982 Drug Ordinance, enacted under President Ershad's government on the advice of a WHO advisory panel. The Ordinance banned the production and import of approximately 1,700 non-essential or harmful products, privileged local manufacturers in a defined list of essential medicines, and imposed market exit requirements on multinationals for lower-end generic segments. This created protected market space for domestic manufacturers to grow without direct multinational competition in priority segments. • **Trade-related aspects of intellectual property (TRIPS) waiver:** As a Least Developed Country (LDC), Bangladesh was exempted from implementing pharmaceutical product patents under the WTO TRIPS Agreement. This exemption allowed Bangladeshi manufacturers to produce patented molecules as generics without paying royalties, dramatically expanding the portfolio of commercially viable products available to local manufacturers. India made the same strategic use of process-patent-only protection from 1970 to 2005; Bangladesh retains this advantage significantly longer due to its LDC status.

Outcomes	• **Domestic self-sufficiency:** Bangladesh now meets approximately 98 percent of its domestic pharmaceutical demand from local production, a transformation from near-total import dependency in the 1980s. • **Export growth:** Bangladesh now exports pharmaceuticals to about 166 countries. Export revenues exceeded USD 200 million in 2023, with ambitions to reach USD 1 billion by 2030. • **Industry structure:** The sector now comprises about 300 manufacturers, with companies such as Square, ACME, Beximco, and Incepta among the largest and most sophisticated generic manufacturers in South and Southeast Asia. • **WHO PQ:** Bangladeshi companies have achieved multiple WHO Prequalifications, enabling access to procurement markets across Africa, Asia, and Latin America.
Lessons for Nigeria	• **Shape the market, don't just support it:** Use decisive policy tools to limit competition in priority medicine segments so local manufacturers can scale. • **Operationalise legal flexibility:** Convert patent and TRIPS flexibilities into an active product expansion and manufacturing playbook. • **Domestic dominance before global reach:** Secure local supply at scale first, then leverage that base to compete in export markets like AfCFTA.

Strategic recommendations

Strengthen API localization

Investment in local Active Pharmaceutical Ingredient (API) manufacturing capability represents the single most strategic intervention available to Nigerian pharmaceutical sector stakeholders. The Sagamu API facility and similar projects must be treated as national infrastructure priorities, with coordinated support from federal investment promotion agencies, development finance institutions (including the African Development Bank and IFC), and industry associations. Decoupling from global API price shocks, particularly the volatility associated with Indian and Chinese suppliers, is not merely a cost management exercise; it is a national health security imperative.

Manufacturers should conduct immediate API sourcing vulnerability assessments, identifying which of their critical ingredients are single-sourced from geographies with high supply disruption risk. Those operating with greater than 70% API concentration from single-country sources should initiate supplier diversification strategies within 12 months.

Scale Medipool adoption

The Medipool Group Purchasing Organization represents one of the most powerful demand-side interventions in the history of Nigerian pharmaceutical policy. Manufacturers that align their production planning cycles with Medipool's aggregated procurement schedules gain immediate access to volume-based financial stability, reducing the demand uncertainty that has historically made capacity investment unattractive for local manufacturers. We recommend that all manufacturers supplying essential medicines to the public sector engage proactively with Medipool's planning calendars, harmonizing production cycles to maximize the efficiency benefits of aggregated procurement.

Deploy GS1 serialization

Compliance with NAFDAC's mandatory GS1 serialization requirements under the "Traceability 2.0" framework is no longer optional, it is a prerequisite for continued market access. Organizations that have not yet initiated serialization implementation programs should treat this as an emergency priority, given the lead times involved in technology procurement, system integration, staff training, and regulatory validation. Early movers in serialization not only achieve compliance; they build the data infrastructure necessary to deploy AI-driven demand sensing and counterfeit detection capabilities that create sustainable competitive differentiation.

Invest in solar cold logistics infrastructure

The transition from diesel-powered cold chain infrastructure to solar-integrated refrigerated logistics systems is simultaneously an ESG imperative, a cost management strategy, and a competitive differentiator. Diesel price volatility, exacerbated by Nigeria's subsidy reform program, has made traditional cold chain economics increasingly unpredictable. Solar-powered cold hubs with Internet of Things (IoT) enabled monitoring deliver triple benefits: reduced operational carbon footprint (meeting ESG requirements of international procurement organizations), insulation from diesel price shocks (improving margin predictability), and superior temperature monitoring reliability (reducing cold chain failure rates).

Build digital supply chain architecture

Organisations should develop a comprehensive digital supply chain architecture strategy that sequences technology investments for maximum compounding impact.

The recommended sequence for most Nigerian pharmaceutical operators is: first, deploy real-time inventory visibility platforms across the distribution network; second, implement AI-enabled demand forecasting to reduce stockout and overstock cycles; third, deploy blockchain-anchored product authentication for high-value and high-risk Stock Keeping Units (SKUs); and fourth, build toward integrated digital twin simulation capability for strategic scenario planning.

Each investment builds the data infrastructure that makes subsequent investments more valuable.

Sources:

- Nigeria Private Health Sector Market Outlook 2026
- NAFDAC's AI reforms target top WHO regulatory rating
- Adeyeye's reforms lift Nigeria pharma output to 50%, secure global regulatory ranking - Businessday NG
- https://www.vanguardngr.com/2025/04/nafdac-rolls-out-regulatory-framework-to-ensure-quality-efficacy-of-generic-medicines/
- NAFDAC Unfolds Regulatory Actions to Deepen Medicine Security
- IFC Nigeria Country Private Sector Diagnostic Report 2024
- Export Dynamics of the Pharmaceutical Industry in Bangladesh
- https://www.linkedin.com/posts/medipoolng_fg-moves-to-lower-medicine-costs-signs-mou-activity-7431447228319281152-d4rd/
- https://newtelegraphng.com/nafdac-unveils-new-measures-to-tackle-fake-drugs-nationwide/
- https://www.premiumtimesng.com/health/health-news/828629-nigerias-dependence-on-imported-medicines-reduced-from-70-to-60-nafdac.html
- https://www.bu.edu/gdp/2021/09/30/the-case-for-policy-space-bangladeshs-pharmaceutical-sector-and-access-to-medicines/
- https://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India
- https://ispe.org/pharmaceutical-engineering/march-april-2025/indian-pharmaceutical-industry-creating-global-impact
- https://damore-mckim.northeastern.edu/cem/resources/from-copycats-to-the-pharmacy-of-the-world-how-indias-pharmaceutical-industry-adapted-to-trade-related-global-intellectual-property-reform/
- https://www.weforum.org/stories/2023/03/in-africa-s-free-trade-area-investment-in-pharmaceuticals-means-impact-and-profit/
- https://www.researchsquare.com/article/rs-3977061/v1
- Bangladesh's pharma industry moves from import dependence to global prominence | The Business Standard

Contact us

Mohammed Adama
Partner and Head,
Consumer and Industrial Markets Sector
KPMG West Africa
E: mohammed.adama@ng.kpmg.com

Bimpe Afolabi
Partner,
Internal Audit & Global Risk Compliance Services
KPMG West Africa
E: bimpe.afolabi@ng.kpmg.com

Dunni Okegbemila
Partner,
Consumer and Industrial Markets
KPMG West Africa
E: dunni.okegbemila@ng.kpmg.com

Contributors

Bukunmi Olaniyonu
E: bukunmi.olaniyonu@ng.kpmg.com

Fatai Shuaib
E: fatai.shuaib@ng.kpmg.com

Quadri Olakunle
E: quadri.olakunle@ng.kpmg.com

Christabel Ofili
E: christabel.ofili@ng.kpmg.com

Creative Designer

Olubunmi Falade
E: olubunmi.falade@ng.kpmg.com

home.kpmg/ng
home.kpmg/socialmedia